BusinessEarth Science Tech Initiates its Cannabis Cannabinoid-Based Composition of its 2 New Pharmaceutical Drugs and 3 Nutraceutical Patent StudiesBy Nasdaq OMXFeb 23, 2017, 11:45 AM UTC
BusinessStudy Published in PAIN Reveals Nicotinamide Riboside is an Effective Tool in Relieving Chemotherapy-Induced Peripheral Neuropathy Induced by a Common Anticancer AgentBy Nasdaq OMXFeb 22, 2017, 11:30 AM UTC
BusinessMyriad’s BRACAnalysis CDx® Test Successfully Identified Metastatic Breast Cancer Patients with Improved Outcomes from AstraZeneca's PARP Inhibitor, OlaparibBy Nasdaq OMXFeb 17, 2017, 12:30 PM UTC
BusinessMyriad’s Prolaris® Test Significantly Improves the Risk Classification for One Third of Men Diagnosed with Localized Prostate CancerBy Nasdaq OMXFeb 17, 2017, 12:05 PM UTC
BusinessETST and its wholly owned subsidiary, Cannabis Therapeutics, Signs Joint Venture with Smart Medicines GMP for the Development of its Cannabis Cannabinoid-Based Drugs & NutraceuticalsBy Nasdaq OMXFeb 14, 2017, 12:15 PM UTC
BusinessLifeVantage Announces Financial Results for the Second Quarter of Fiscal 2017By Nasdaq OMXFeb 8, 2017, 9:06 PM UTC
BusinessLifeVantage Announces Financial Results for the Second Quarter of Fiscal 2017By Nasdaq OMXFeb 8, 2017, 9:06 PM UTC
BusinessEarth Science Tech Announces New Wholly Owned Subsidiary, Cannabis Therapeutics Inc., to Develop & Launch its Cannabis Cannabinoid-Based Drugs & Nutraceuticals Using its Cannabinoid-Cannabidiol (CBD) Patent, IP and TechnologyBy Nasdaq OMXFeb 6, 2017, 12:45 PM UTC
